Information on selecting the most advantageous offer - request for proposal number RFP 21433– REAGENTS

In connection with obtaining from the National Centre for Research and Development a grant for the project „Clinical development of an innovative anti-cancer drug using the mechanism of  reactivation of p53 protein” (project no. MAZOWSZE/0012/19) under R&D programme ,,Ścieżka dla Mazowsza”, acting on the basis of Article 10 of the financial project support contract, Adamed Pharma S.A. informs that the contract will be awarded to the following companies that havepresented the most advantageous offer:

• Merck Life Science Sp. z o.o. items: 6, 8, 26, 32
• Hurt-Chem Hurtownia Odczynników Chemicznych Piotr Bartochaitems: 9
• Trimen Chemicals Sp. z o.o. items: 3, 5, 10, 11, 15, 16, 17, 18, 19, 21, 23, 24, 25, 29, 30, 31, 35, 37, 38, 40
• Chemtronica AB items: 22, 27, 28, 34
• Chemat Adam Taszneritems: 1, 2, 4, 7, 12, 13, 14, 20, 33, 36, 39